GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Revenue

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Revenue : $0.29 Mil (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Revenue?

Aequus Pharmaceuticals's revenue for the three months ended in Sep. 2023 was $0.01 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.29 Mil. Aequus Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

Warning Sign:

Aequus Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Aequus Pharmaceuticals was -50.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 10 years, Aequus Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 18.10% per year. The lowest was -20.60% per year. And the median was 6.75% per year.


Aequus Pharmaceuticals Revenue Historical Data

The historical data trend for Aequus Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Revenue Chart

Aequus Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.24 2.02 2.12 1.02

Aequus Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.27 0.26 0.28 0.01

Competitive Comparison of Aequus Pharmaceuticals's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Revenue falls into.



Aequus Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals  (OTCPK:AQSZF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Aequus Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Headlines